About: Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events
Creator	Gülsen, Askin Jappe, Uta Wedi, Bettina
Source	PMC
abstract	PURPOSE: Biotechnological substances (BSs) are strongly relied upon to prevent rejection of transplanted organs, and to treat oncological, allergological, and other inflammatory diseases. Allergic reactions to partly foreign biologics can occur due to their potential immunogenicity. The severity of an immune response to a biological drug may range from no clinical significance to a severe, life-threatening anaphylactic reaction. METHODS: Detailed searches were performed on Pubmed, Web of Science, and Google Scholar to include all available publications. In addition, the Food and Drug Administration, the European Medicines Agency, and British Columbia Cancer Agency Drug Manual databases were screened for hypersensitivity reaction (HSR), infusion reaction, injection site reaction, urticaria, and anaphylaxis for individual BSs. RESULTS: Treatment with BSs can cause various types of HSR. These are mentioned in the literature with definitions such as allergic reactions, anaphylactoid reactions, anaphylaxis, HSR, infusion reactions, injection site reactions, cytokine release syndrome, and urticaria. Due to the overlap in signs and symptoms in the reported descriptions, it is not always possible to differentiate these reactions properly according to their pathomechanism. Similarly, many data reported as anaphylaxis actually describe severe anaphylactic reactions (grades III or IV). CONCLUSION: There is an urgent need for a simpler symptom- or system-based classification and scoring system to create an awareness for HSRs to BSs. A better understanding of the pathophysiology of HSRs and increased clinical experience in the treatment of side effects will provide timely control of unexpected reactions. As a result, immunotherapy with BSs will become safer in the future.
has issue date	2020-05-12(xsd:dateTime)
bibo:doi	10.1007/s40629-020-00126-6
bibo:pmid	32421085
has license	cc-by
sha1sum (hex)	d4294b23052e2abd78d280a727952cccfaf50150
schema:url	https://doi.org/10.1007/s40629-020-00126-6
resource representing a document's title	Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events
has PubMed Central identifier	PMC7223134
has PubMed identifier	32421085
schema:publication	Allergo J Int
resource representing a document's body	covid:d4294b23052e2abd78d280a727952cccfaf50150#body_text
is schema:about of	named entity 'allergy' named entity 'Hypersensitivity reactions' named entity 'intravenously' named entity 'EMA 2018' named entity 'placebo' named entity 'angioedema' named entity 'Natalizumab' named entity 'EMA 2019' named entity 'immunosuppressant' named entity 'sarcoidosis' named entity 'mAb' named entity 'EMA 2016' named entity 'TNF-α' named entity 'Pembrolizumab' named entity 'inflammation' named entity 'colorectal carcinoma' named entity 'IL-1β' named entity 'rituximab' named entity 'treatment group' named entity 'edema' named entity 'subcutaneously' named entity 'rhinitis' named entity 'skin rash' named entity 'rash' named entity 'nausea' named entity 'bronchospasm' named entity 'hepatotoxicity' named entity 'papule' named entity 'CD80' named entity 'FDA' named entity 'gelatine' named entity 'urticaria' named entity 'anaphylaxis' named entity 'Nivolumab' named entity 'increased liver enzymes' named entity 'antibodies' named entity 'galactose' named entity 'neuromyelitis optica spectrum disorder' named entity 'clinical experience' named entity 'Infliximab' named entity 'antibody' named entity 'IgE' named entity 'allergic' named entity 'Urticaria' named entity 'FDA' named entity 'erythematous rash' named entity 'TNF-α' named entity 'contact dermatitis' named entity 'anaphylaxis' named entity 'mAb' named entity 'headache' named entity 'murine' named entity 'IgE' named entity 'anaphylaxis' named entity 'colitis' named entity 'Adverse drug reactions' named entity 'respiratory failure' named entity 'urticaria' named entity 'symptom' named entity 'fever' named entity 'IRs' named entity 'diarrhea' named entity 'pembrolizumab' named entity 'severe or life-threatening' named entity 'congenital heart disease' named entity 'Nintedanib' named entity 'hypotension' named entity 'generalized myasthenia gravis' named entity 'idiopathic pulmonary fibrosis' named entity 'hypersensitivity' named entity 'FDA labels' named entity 'Willebrand' named entity 'pruritus' named entity 'biologics' named entity 'Alefacept' named entity 'rash' named entity 'malaise' named entity 'dizziness' named entity 'allergic reactions'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software